Navigation Links
Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
Date:10/24/2011

SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, for the diabetes, cancer, dermatology and drug delivery markets, today announced its upcoming poster presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, taking place October 27-29 in Brussels, Belgium. Halozyme's PEGPH20 is a PEGylated form of rHuPH20 that is being evaluated in an ongoing Phase 2 clinical trial in patients with stage IV previously untreated pancreatic cancer. The poster and abstract will also be published in the "European Journal of Cancer" proceeding book of the conference. Details of the poster session and discussion are as follows:

Thursday, October 27, 2011

12:00 – 8:30 p.m. CET: Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in patients with advanced solid tumors   (Discussion from 6:00 – 8:30 p.m. CET)

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Hercept
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  GenSpera, Inc. (OTCQB: GNSZ), a ... of cancer, announces that Kareg Corporation,s Director of ... the following research report on  the company. ... of Research, Kareg Corporation, Initiating Coverage with a ... full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf GNSZ ...
(Date:7/14/2014)... 2014  Otonomy, Inc., a clinical-stage biopharmaceutical company focused ... diseases and disorders of the inner and middle ear, ... statement on Form S-1 with the U.S. Securities and ... offering of shares of its common stock. All shares ... will be offered by Otonomy. The number of shares ...
(Date:7/14/2014)... and LONDON , July 14, 2014 ... IXICO plc (AIM: IXI) jointly announced today the formation ... companies. Dr. Edward Ashton , Ph.D., chief scientific ... have seven members. "The formation of this ... the international commercial and operational alliance we signed with ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Otonomy Files Registration Statement for Proposed Initial Public Offering 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9
... YORK, Sept. 21 An eminent international panel of ... LLY ) to receive a World Business and ... successful partnerships in the battle against multidrug-resistant tuberculosis (MDR-TB). ... of The Lilly MDR-TB Partnership demonstrate a clear linkage ...
... According to Millennium Research Group (MRG), the global authority ... new growth factors, combined with greater variety and improved features ... market to nearly $2.3 billion through 2015. Medtronic ... AMPLIFY , is set to be released in the US ...
Cached Medicine Technology:Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 2Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 3Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 2Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 3
(Date:7/14/2014)... Laurel, N.J. (PRWEB) July 14, 2014 ... Mount Laurel, has announced the publication of its first military ... plane crash on Black Thursday in October 1943 and 19 ... March to return home and build the American dream. ... II and the American dream (Amazon) is a ...
(Date:7/14/2014)... According to a recent study ... a connection between women with high levels of a ... doctors have theorized about the role stress plays in ... provide scientific support. , “Stress, if very significant, can ... Barmat, an OB/GYN who specializes in reproductive endocrinology and ...
(Date:7/14/2014)... There’s an old adage that says first impressions make ... say the products offered in their preorder event not only ... The Lash Palette for $40,” said Jenelle Paris, founder and ... explained that the first 1,000 have already been sold during ... on to point out that her company is an online ...
(Date:7/14/2014)... Jordan Valley Medical Center is expanding the ... center set to open by the fall of 2015. ... west of I-15 in the Salt Lake Valley providing ... Valley Medical Center has partnered with Elekta, a company ... for radiation therapy, radiosurgery and brachytherapy, to bring Versa ...
(Date:7/14/2014)... For the Spanish Royal Academy, senescent is he who ... the dictionary: not only is senescence not a synonym ... the organism. Cellular senescence is such a badly named ... area think it needs another name. That is the ... Research Centre (CNIO), one of the world,s leading experts ...
Breaking Medicine News(10 mins):Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2Health News:Abington Health Physician Addresses Link Between Stress and Infertility 2Health News:Abington Health Physician Addresses Link Between Stress and Infertility 3Health News:The Lash Palette Preorder Event Has Officially Begun 2Health News:Jordan Valley Medical Center Set to Break Ground with New $10 Million Cancer Center 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3
... diabetes research in India, even though the country remains one ... disease. Indian scientists have published only one percent of the ... Indian Journal of Medical Research, in an assessment of the ... India published a total of 3068 papers during the 30 ...
... 25 million dollar space programme, will carry out scientific ... cells in outer space, reports said Wednesday. ... and the crystallisation of protein, said Abdul Rahman Abdul ... National University of Malaysia. ,"The research is ...
... their health by using over the counter nutritional supplements ... cons with the health professionals managing their conventional treatment. ... Griffith's School of Nursing, says that though some complementary ... have side effects or interact with conventional medications. ...
... School of Medicine in St. Louis, Missouri, have found ... to treatments for deadliest poisons like Ricin, cholera toxin, ... deadly strains of E. coli bacteria, these toxins travel ... Golgi network and endoplasmic reticulum before interrupting protein synthesis. ...
... a developing female sheep foetus to low doses of commonly ... ,The study was conducted by a team ... of Aberdeen, Scotland, UK. ,As part of the ... a cocktail of chemicals and heavy metals in an animal ...
... New research by the British charity Save the Children, shows ... nutritious diet , they would have to spend three times ... reported by The Independent, this would amount to a 1,700 ... research calculated how much a healthy diet, based on local ...
Cached Medicine News:Health News:India's Share in Global Diabetes Research is One Percent 2Health News:Diabetics Risking Health by Using Alternative Medications Without Consultation 2Health News:For Bangladeshis, a Nutritious Diet Would Cost 1,700 Pounds Per Week 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: